June 30, 2017

Alcyone Lifesciences enter into feasibility study agreement with Pfizer Inc. (NYSE:PFE)

Alcyone Lifesciences, Inc., a leader in precision advanced central nervous system (CNS) delivery systems announced that it has entered into a feasibility study agreement with Pfizer Inc. (NYSE:PFE) in the area of genetic therapy targeting rare and orphan neurological disorders. The feasibility study combines Alcyone’s proprietary PulsarTM Advanced Intrathecal Precision Delivery Platform Technology and Pfizer’s Recombinant Adeno-associated Viral Vector (rAAV) gene therapy technology in an effort to develop a method of administering genetic therapies that may address neurological disorders more effectively.

Pfizer Inc. (NYSE:PFE) shares tanked -0.36% to $33.63 on Thursday.

Gene therapy is a potentially transformational therapeutic approach for patients suffering from certain rare and orphan neurological disorders, which focuses on the use of one-time treatments that may address the fundamental cause of the disease caused by genetic mutations. The very potential of this therapy is dependent on the utilization of highly effective and reliable delivery technology, and biodistribution of the viral vectors, such as rAAV, that carry the corrective genetic material to the targets of interest in the CNS. This is particularly critical in CNS gene therapy, because there is one opportunity to get the appropriate concentration of active molecule to the right targets associated with the disease in order to achieve a successful procedure.

Technical Stock Analysis

Shares outstanding are recorded as 6.01B and total shares floated are 5.94B. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 1.10. Company’s distance from 20 day simple moving average is 1.85% and distance from 50-Day simple moving average is 1.77%.

Best time to invest in stock market is when things are on odd side, and it’s not easy how to pick stocks. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Stock has got OUTPERFORM rating from 7 of Thomson Reuters analysts, 10 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for PFE is $37.35 while analysts mean recommendation is 2.50.

Pfizer Inc. (NYSE:PFE) yearly performance is -3.94% and net profit margin is 13.90%. Annual EPS Growth of past 5 years is 3.30%. The current share price indicates that stock is -10.06% away from its one year high and is moving 12.74% ahead of its 52-week low.

Lindsay Corporation (NYSE:LNN) has reported a 13.56 percent rise in profit for the quarter ended May 31, 2017. The company has earned $10.95 million, or $1.02 a share in the quarter, compared with $9.64million, or $0.90 a share for the same period last year. Revenue during the quarter grew 7.23 percent to $151.53 million from $141.32 million in the previous year period. Gross margin for the quarter expanded 71 basis points over the previous year period to 30.29 percent. Total expenses were 88.51 percent of quarterly revenues, down from 89.16 percent for the same period last year. This has led to an improvement of 65 basis points in operating margin to 11.49 percent.

On 29 June 2017, Lindsay Corporation (NYSE:LNN) shares moved to $91.42 after starting the day at $89.00. Stock has got OUTPERFORM rating from 0 of Thomson Reuters analysts, 6 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for LNN is $79.00 while analysts mean recommendation is 3.00.

At the movement Lockheed Martin Corporation (NYSE:LMT) is under coverage by number of analysts. Buy rating has been given by 8 analysts to the company stock whereas 0 given UNDERPERFORM rating to stock and 10 given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is Mean Rating on scale of 1-5. Analysts mean target price for Lockheed Martin Corporation (NYSE:LMT) is $287.82 while their mean recommendation is 2.20 (1=Buy, 5=sell).

If we look at stock performance in last active day trading, we see that stock has moved tanked -1.17% to end the day at $276.73. The current share price indicate that stock is -2.89% away from its one year high and is moving 21.11% ahead of its 52-week low.

Leave a Reply

Your email address will not be published. Required fields are marked *